NCT04489719View on ClinicalTrials.gov

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

RecruitingOBSERVATIONAL
Enrollment

48

Participants

Timeline

Start Date

April 16, 2021

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2029

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Radium Ra 223 Dichloride

Given IV

Trial Locations (4)

21287

RECRUITING

Johns Hopkins University, Baltimore

53705

RECRUITING

University of Wisconsin-Madison, Madison

59715

ACTIVE_NOT_RECRUITING

Bozeman Health Deaconess Hospital, Bozeman

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of Washington

OTHER

NCT04489719 - Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter